Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Morgan

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Blood|January 31, 2023
Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemiaStephen K Tahir, Emiliano Calvo, Benedito A Carneiro, et al.
Journal for Immunotherapy of Cancer|June 28, 2020
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trialFederica Cappuccini, Richard Bryant, Emily Pollock, et al.
European Journal of Haematology|December 20, 2022
Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registryJames Nguyen, Cameron Wellard, Eliza Chung, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 23, 2014
Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's diseasePatrick Bradley, Ron Akehurst, Clive Ballard, et al.
Trials|July 22, 2022
NeuroSAFE PROOF: study protocol for a single-blinded, IDEAL stage 3, multi-centre, randomised controlled trial of NeuroSAFE robotic-assisted radical prostatectomy versus standard robotic-assisted radical prostatectomy in men with localized prostate cancerEoin Dinneen, Jack Grierson, Ricardo Almeida-Magana, et al.
Molecular Cancer Therapeutics|June 6, 2022
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug ConjugateShweta Singh, Laura Serwer, Amy DuPage, et al.
Blood|May 3, 2024
ABBV-319: a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignanciesChewei Anderson Chang, Ethan Emberley, Aloma L D'Souza, et al.
Blood Advances|March 26, 2020
RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AMLAnna L Brown, Peer Arts, Catherine L Carmichael, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Blood|January 31, 2023
Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemiaStephen K Tahir, Emiliano Calvo, Benedito A Carneiro, et al.
Journal for Immunotherapy of Cancer|June 28, 2020
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trialFederica Cappuccini, Richard Bryant, Emily Pollock, et al.
European Journal of Haematology|December 20, 2022
Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registryJames Nguyen, Cameron Wellard, Eliza Chung, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 23, 2014
Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's diseasePatrick Bradley, Ron Akehurst, Clive Ballard, et al.
Trials|July 22, 2022
NeuroSAFE PROOF: study protocol for a single-blinded, IDEAL stage 3, multi-centre, randomised controlled trial of NeuroSAFE robotic-assisted radical prostatectomy versus standard robotic-assisted radical prostatectomy in men with localized prostate cancerEoin Dinneen, Jack Grierson, Ricardo Almeida-Magana, et al.
Molecular Cancer Therapeutics|June 6, 2022
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug ConjugateShweta Singh, Laura Serwer, Amy DuPage, et al.
Blood|May 3, 2024
ABBV-319: a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignanciesChewei Anderson Chang, Ethan Emberley, Aloma L D'Souza, et al.
Blood Advances|March 26, 2020
RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AMLAnna L Brown, Peer Arts, Catherine L Carmichael, et al.
Pageof 7